Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica · 2026
PSMA PET/CT in diagnosing and staging high grade prostate cancer: accuracy and cost-effectiveness.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pepe Pietro, Pepe Ludovica, Pepe Gabriele, Fiorentino Vincenzo
Аннотация
INTRODUCTION: To evaluate accuracy and costeffectiveness of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) as single procedure in diagnosing and staging high grade prostate cancer (PCa).
MATERIALS AND METHODS: From June 2022 to December 2025, 330 men (median age: 65 years) underwent transperineal prostate biopsy for the suspicion of high grade PCa (PSA >20 ng/ml and/or suspicious digital rectal examination). All the patients underwent PSMA PET/CT targeted biopsy of intraprostatic lesions suspicious for PCa (Standard Uptake Value >8) combined with extended prostate biopsy.
RESULTS: Median PSA was 30.5 ng/ml (range: 20-785 ng/ml) and 135/330 (41%) men had positive DRE; a csPCa was found in 325/330 (98.5%) patients and 297/325 (91.4%) had a Gleason score >8/ISUP Grade Group >4. Clinical staging by PSMA PET/CT demonstrated: 130 (40%) cT2PCa vs 195 (60%) cT3PCa cases; in detail, 95/325 (29.2%) had positive nodes, 60 (18.5%) bone metastases and 40 (12.3%) multiple metastases. The overall reimbursement for diagnosing PCa in the 330 patients submitted to prostate biopsy was 471,883,5 €.; using PSMA PET/CT without MRI the cost of this latter procedure could be spared for a total of 71,016 €.
CONCLUSIONS: PSMA PET/CT as a single imaging procedure demonstrated an high accuracy in diagnosing and staging high grade PCa, moreover, improved cost-effectiveness and allowed to start quickly therapy.
MATERIALS AND METHODS: From June 2022 to December 2025, 330 men (median age: 65 years) underwent transperineal prostate biopsy for the suspicion of high grade PCa (PSA >20 ng/ml and/or suspicious digital rectal examination). All the patients underwent PSMA PET/CT targeted biopsy of intraprostatic lesions suspicious for PCa (Standard Uptake Value >8) combined with extended prostate biopsy.
RESULTS: Median PSA was 30.5 ng/ml (range: 20-785 ng/ml) and 135/330 (41%) men had positive DRE; a csPCa was found in 325/330 (98.5%) patients and 297/325 (91.4%) had a Gleason score >8/ISUP Grade Group >4. Clinical staging by PSMA PET/CT demonstrated: 130 (40%) cT2PCa vs 195 (60%) cT3PCa cases; in detail, 95/325 (29.2%) had positive nodes, 60 (18.5%) bone metastases and 40 (12.3%) multiple metastases. The overall reimbursement for diagnosing PCa in the 330 patients submitted to prostate biopsy was 471,883,5 €.; using PSMA PET/CT without MRI the cost of this latter procedure could be spared for a total of 71,016 €.
CONCLUSIONS: PSMA PET/CT as a single imaging procedure demonstrated an high accuracy in diagnosing and staging high grade PCa, moreover, improved cost-effectiveness and allowed to start quickly therapy.